Your browser doesn't support javascript.
loading
HER2/neu testing in primary colorectal carcinoma.
Ingold Heppner, B; Behrens, H-M; Balschun, K; Haag, J; Krüger, S; Becker, T; Röcken, C.
Afiliación
  • Ingold Heppner B; Department of Pathology, Campus Mitte, Charité University Hospital, 10117 Berlin, Germany.
  • Behrens HM; Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
  • Balschun K; Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
  • Haag J; Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
  • Krüger S; Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
  • Becker T; Department of General Surgery and Thoracic Surgery, Christian-Albrechts-University, 24105 Kiel, Germany.
  • Röcken C; Department of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
Br J Cancer ; 111(10): 1977-84, 2014 Nov 11.
Article en En | MEDLINE | ID: mdl-25211663
BACKGROUND: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives. The role of HER2/neu in colorectal carcinoma is controversially discussed, as discrepant data has been reported. METHODS: Here, we retrospectively assessed the prevalence of HER2/neu positivity in a large series of colorectal carcinoma, testing HER2/neu status according to current recommendations. We correlated the results to clinico-pathological data and patient survival. RESULTS: Overall, in 1645 primary colorectal carcinoma cases, 1.6% of the cases were HER2/neu positive. HER2/neu positivity significantly correlated with higher UICC stages (P=0.017) and lymph node metastases (P=0.029). In the subgroup of sigmoideal and rectal carcinomas, positive HER2/neu status was associated with T-category (P=0.041) and higher UICC stages (P=0.022). Although statistically not significant, HER2/neu-positive colorectal carcinomas displayed a tendency to poorer overall survival. CONCLUSIONS: These results illustrate the importance of testing HER2/neu by approved diagnostic techniques and scoring systems. We assume that although the prevalence of HER2/neu positivity in colorectal carcinoma is low, HER2/neu testing in advanced, nodal-positive colorectal carcinoma is reasonable, offering a potential target in high risk colorectal carcinoma.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Receptor ErbB-2 Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Receptor ErbB-2 Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido